While it might not have delivered yet in untreated non-small cell lung cancer (NSCLC), the PD-L1 immunotherapy Imfinzi (durvalumab) is proving itself an effective treatment for patients with the disease further down the line.
The drug’s developer, Anglo-Swedish pharma major AstraZeneca (LSE: AZN), has presented results showing that it met the second primary endpoint of improved overall survival (OS) in the Phase III PACIFIC study in unresectable Stage III, or locally-advanced, NSCLC patients whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).
A planned interim analysis concluded that the trial has met this endpoint by showing statistically-significant OS benefit with clinically-meaningful improvement in patients receiving Imfinzi compared to placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze